Skip to main contentSkip to navigationSkip to search
HNSA (, %) SEK
Hansa Biopharma logotype

Annual Report 2008 (In Swedish)

Regulatory information
The annual report for Hansa Medical 2008 (In Swedish) is available as PDF the 15th of April 2009 through www.hansamedical.com. A print version of the annual report can be ordered through info@hansamedical.com

Lund, April 15, 2009Hansa Medical AB (publ)For more information, please contact:Emanuel Björne, CEOMobile: +46 (0)70 717 54 77E-mail: emanuel.bjorne@hansamedical.comHansa Medical is a preclinical and early clinical biopharmaceutical development company focused on inflammation. The company develops three primary products, IdeS, anti-alpha-11 and HMD-301. IdeS is a novel treatment prior to organ transplantation. Anti-alpha-11 is a novel and more specific rheumatoid arthritis treatment. HMD-301 is a novel diagnostic method for diagnosis and prognosis of severe sepsis. Hansa Medical is publicly traded at NASDAQ OMX First North under ticker symbol HMED.

Downloads